Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

被引:32
|
作者
Yamada, Ryoko [1 ]
Hiramatsu, Naoki [2 ]
Oze, Tsugiko [1 ]
Urabe, Ayako [1 ]
Tahata, Yuki [1 ]
Morishita, Naoki [3 ]
Kodama, Takahiro [1 ]
Hikita, Hayato [1 ]
Sakamori, Ryotaro [1 ]
Yakushijin, Takayuki [4 ]
Yamada, Akira [5 ]
Hagiwara, Hideki [10 ]
Mita, Eiji [6 ]
Oshita, Masahide [7 ]
Itoh, Toshifumi [8 ]
Fukui, Hiroyuki [11 ]
Inui, Yoshiaki [12 ]
Hijioka, Taizo [13 ]
Inada, Masami [14 ]
Katayama, Kazuhiro [9 ]
Tamura, Shinji [3 ]
Inoue, Atsuo [4 ]
Imai, Yasuharu [15 ]
Tatsumi, Tomohide [1 ]
Hamasaki, Toshimitsu [16 ]
Hayashi, Norio [10 ]
Takehara, Tetsuo [1 ]
机构
[1] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[2] Osaka Rosai Hosp, Dept Gastroenterol & Hepatol, Sakai, Osaka, Japan
[3] Minoh City Hosp, Dept Gastroenterol & Hepatol, Mino, Japan
[4] Osaka Gen Med Ctr, Dept Gastroenterol & Hepatol, Osaka, Japan
[5] Sumitomo Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[6] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Natl Hosp, Osaka, Japan
[7] Osaka Police Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[8] Japan Community Hlth Care Org, Dept Gastroenterol & Hepatol, Osaka Hosp, Osaka, Japan
[9] Osaka Int Canc Inst, Dept Gastroenterol & Hepatol, Osaka, Japan
[10] Kansai Rosai Hosp, Dept Gastroenterol & Hepatol, Amagasaki, Hyogo, Japan
[11] Yao Municipal Hosp, Dept Gastroenterol & Hepatol, Yao, Japan
[12] Hyogo Prefectural Nishinomiya Hosp, Dept Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan
[13] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Minami Med Ctr, Kawachi Nagano, Japan
[14] Toyonaka City Hosp, Dept Gastroenterol & Hepatol, Toyonaka, Osaka, Japan
[15] Ikeda Municipal Hosp, Dept Gastroenterol & Hepatol, Ikeda, Osaka, Japan
[16] Natl Cerebral & Cardiovasc Ctr, Dept Gastroenterol & Hepatol, Dept Data Sci, Suita, Osaka, Japan
关键词
chronic hepatitis C; pegylated interferon; risk factor; hepatocellular carcinoma; direct-acting antivirals; EARLY TUMOR RECURRENCE; INTERFERON THERAPY; PLUS RIBAVIRIN; ALPHA; IMPACT;
D O I
10.1111/hepr.13310
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment alpha-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed. Methods Among patients prospectively registered for pegylated interferon and ribavirin treatment, 2021 with an SVR without HCC development during the treatment period were followed up. The mean observation period was 49.5 +/- 26.2 months. Results The multivariable Cox regression analysis showed that older age, diabetes mellitus, advanced liver disease, and higher post-treatment AFP level were the independent risk factors throughout the observation period. The annual occurrence rate of HCC was 0.74% in the third year, 0.54% in the fourth year, and 0.40% in the fifth year; it gradually decreased from the third year. Because the time course hazards for HCC changed at 48 months, we separately analyzed its risk factors before and after this change point. The multivariable Cox regression analysis showed that the four above-mentioned factors were significantly related to HCC development within 4 years. Conversely, the univariable Cox regression analysis only identified diabetes mellitus as a significant factor for HCC development after 4 years. Conclusion The frequency of HCC in hepatitis C patients who achieved an SVR from interferon treatment decreased during the observation period, and its risk factors changed between the early and late periods.
引用
收藏
页码:570 / 578
页数:9
相关论文
共 50 条
  • [2] Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response
    Toyoda, Hidenori
    Yasuda, Satoshi
    Shiota, Shohei
    Kumada, Takashi
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (06) : 693 - 697
  • [3] Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection
    Toyoda, Hidenori
    Koshiyama, Yuichi
    Yasuda, Satoshi
    Kumada, Takashi
    Chayama, Kazuaki
    Akita, Tomoyuki
    Tanaka, Junko
    JOURNAL OF VIRAL HEPATITIS, 2024, 31 (03) : 137 - 142
  • [4] Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection
    Toyoda, Hidenori
    Kumada, Takashi
    Tada, Toshifumi
    Kiriyama, Seiki
    Tanikawa, Makoto
    Hisanaga, Yasuhiro
    Kanamori, Akira
    Kitabatake, Shusuke
    Ito, Takanori
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (07) : 1183 - 1189
  • [5] Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy
    Iwasaki, Y
    Takaguchi, K
    Ikeda, H
    Makino, Y
    Araki, Y
    Ando, M
    Kobashi, H
    Kobatake, T
    Tanaka, R
    Tomita, M
    Senoh, T
    Kawaguchi, M
    Shimoe, T
    Manabe, K
    Kita, K
    Shimamura, J
    Sakaguchi, K
    Shiratori, Y
    LIVER INTERNATIONAL, 2004, 24 (06) : 603 - 610
  • [6] Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response
    Toyoda, Hidenori
    Tada, Toshifumi
    Yasuda, Satoshi
    Mizuno, Kazuyuki
    Ito, Takanori
    Kumada, Takashi
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (06) : 1208 - 1214
  • [7] The incidence of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virological response to interferon therapy
    Kobayashi, S.
    Enomoto, M.
    Tamori, A.
    Kawada, N.
    Habu, D.
    Sakaguchi, H.
    Takedal, T.
    Nishiguchi, S.
    Seki, S.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S219 - S219
  • [8] Pathological characteristics of patients who develop primary hepatocellular carcinoma after achieving sustained virologic response for hepatitis C virus infection
    Kondo, Reiichiro
    Akiba, Jun
    Nakashima, Osamu
    Naito, Yoshiki
    Kusano, Hironori
    Nakayama, Masamichi
    Mihara, Yutaro
    Yano, Hirohisa
    HEPATOLOGY, 2017, 66 : 520A - 520A
  • [9] mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Yasuda, Satoshi
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Matono, Tomomitsu
    Nakamura, Shinichiro
    Toyoda, Hidenori
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1164 - 1171
  • [10] HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma
    Merchante, Nicolas
    Merino, Esperanza
    Rodriguez-Arrondo, Francisco
    Tural, Cristina
    Munoz, Josefa
    Delgado-Fernandez, Marcial
    Jover, Francisco
    Galindo, Maria J.
    Rivero, Antonio
    Lopez-Aldeguer, Jose
    Aguirrebengoa, Koldo
    Romero-Palacios, Alberto
    Martinez, Eduardo
    Pineda, Juan A.
    AIDS, 2014, 28 (01) : 41 - 47